Form 4: Repligen Corp Director Glenn P. Muir Reports Acquisition of Restricted Stock Units and Stock Options

Director Glenn P. Muir reports acquisition of 973 restricted stock units and 1,800 stock options in Repligen Corp.

Summary

• Glenn P. Muir, a director of Repligen Corp, reported acquiring 973 restricted stock units on May 15, 2025, at a price of $0.
• These restricted stock units represent a contingent right to receive one share of Repligen Corporation's Common Stock and vest on the earlier of May 15, 2026, or the date of the next annual meeting of shareholders.
• Muir also acquired 1,800 stock options (right to buy) at an exercise price of $123.26 on the same date, expiring on May 15, 2035.
• These options also vest on the earlier of May 15, 2026, or the date of the next annual meeting of shareholders.
• Following these transactions, Muir directly owns 33,256 shares of common stock and 1,800 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard insider transaction. The acquisition of stock options and restricted stock units can be seen as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon future events, specifically the earlier of May 15, 2026, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedules and exercise prices are generally in line with industry standards for incentivizing long-term performance.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation plans for their directors and executives.

Stakeholder Impact

• The acquisition of shares by a director can be viewed positively by shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Repligen Corp, RGEN, Form 4, Glenn P. Muir, Director, Restricted Stock Units, Stock Options, Beneficial Ownership